Subcutaneous gonadotropin therapy for male infertility by hypogonadotropic hypogonadism
P. Moreno, M. Gálvez Moreno, M. Alhambra Expósito, I. Prior Sánchez, C. Muñoz Jimenez, R. Palomares Ortega & P. Benito López
Objetive: Evaluate the efficacy of subcutaneous HCG with or without FSH in male infertility associated to hypogonadotropic hypogonadism (HH).
Patients and methods: Descriptive study of patients with HH treated with HCG s.c. with or without FSH, for fertility objective (20042011). The Treatment was initiated with HCG 500 UI/72 h s.c., periodic monitoring of testosterone and semen analysis was realized, adjusting doses up to 2500 UI/72 h. If no answer obtained after 1 year, combined treatment with FSH s.c. was started. Analyzed data: cause of HH, age, testosterone levels, semen, dose of HCG and FSH treatment. The result has been assessed to the achievement of pregnancy.
Results: Ten patients. 30.6±2.9 years old. Cause of HH: 50% idiopathic, 20% nonfunctioning pituitary adenoma, 10% prolactinoma, 10% acromegaly and 10% craniopharyngioma. Fertility 60%, 22.6±13.5 months treatment time. Only one patient discontinued treatment without success. No presence of side effects. Subgroup result:
Conclusions: Subcutaneous gonadotropin therapy is effective in infertility HH. Treatment with subcuataneous HCG alone is successful. No presence of side effects.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Table 1 Subgroup results.
|Less than 24 months (n=6)||More than 24 months (n=4)|
|Doses HCG (UI/72 h)||1250±612.4||2125±750 |